Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 30
- Registration Number
- NCT05526924
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Theravia
- Target Recruit Count
- 33
- Registration Number
- NCT05470270
- Locations
- 🇫🇷
InterCommunal Hospital Centre of Creteil, Créteil, France
🇫🇷Necker University Hospital, Paris, France
🇫🇷Robert Debré Hospital, Paris, France
Hydroxyurea and EPO in Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Julia Xu
- Target Recruit Count
- 15
- Registration Number
- NCT05451940
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
🇳🇬Lagos University Teaching Hospital, Lagos, Nigeria
Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria in the Community
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Barau Dikko Teaching Hospital
- Target Recruit Count
- 217
- Registration Number
- NCT05434000
- Locations
- 🇳🇬
Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 90
- Registration Number
- NCT05357482
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Brown University
- Target Recruit Count
- 400
- Registration Number
- NCT05285917
- Locations
- 🇦🇴
Hospital Geral dos Cajueiros, Luanda, Angola
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT05142254
- Locations
- 🇳🇬
Murtala Mohammed Specialist Hospital, Kano, Nigeria
🇳🇬Aminu Kano Teaching Hospital, Kano, Nigeria
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 3
- Registration Number
- NCT05005182
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Global Health Uganda LTD
- Target Recruit Count
- 270
- Registration Number
- NCT04750707
- Locations
- 🇺🇬
Global Health Uganda, Kampala, Uganda
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Theravia
- Target Recruit Count
- 2093
- Registration Number
- NCT04707235
- Locations
- 🇫🇷
Bordeaux Hospital Adults, Bordeaux, France
🇫🇷Bordeaux Hospital Children, Bordeaux, France
🇫🇷Tours Regional University Hospital Center Adults, Chambray-lès-Tours, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.